Top

Gepubliceerd in:

2018 | OriginalPaper | Hoofdstuk

8 Vroegdiagnostiek, total body scans en bevolkingsonderzoek: verbetering of valse verwachting?

Auteur : Yolanda van der Graaf

Uitgeverij: Bohn Stafleu van Loghum

Samenvatting

Vroegdiagnostiek, screenen, betekent dat je ziekte opspoort voordat deze symptomen geeft. Intuïtief is het aantrekkelijk maar de baten vallen vaak tegen en dikwijls blijkt het middel erger dan de kwaal. Vroegdiagnostiek en preventie zijn niet hetzelfde.

vorige hoofdstuk 7 Weesgeneesmiddelen vanuit het perspectief van de patiënt

volgende hoofdstuk Intermezzo: Werkelijk bijdragen aan lotsverbetering

Alleen toegankelijk voor geautoriseerde gebruikers

Korevaar DA, Bossuyt PM. STARD 2015 voor de evaluatie van diagnostische tests. Ned Tijdschr Geneeskd 2016;160:D113.

Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms: The UK Small Aneurysm Trial Participants. Lancet1998;352:1649-55.

Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB, et al.; COURAGE Trial Investigators. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med 2015;373:1937-46.CrossRef

Flor N, Di Leo G, Squarza SA, Tresoldi S, Rulli E, Cornalba G, et al. Malignant incidental extracardiac findings on cardiac CT: systematic review and metaanalysis. Am J Roentgenol 2013;201:555-64.CrossRef

Buckens CF, Verkooijen HM, Gondrie MJ, Jairam P, Mali WP, van der Graaf Y. Unrequested findings on cardiac computed tomography: looking beyond the heart. PLoS One 2012;7:e32184.CrossRef

Prasad V, Lenzer J, Newman DH. Why cancer screening has never been shown to ‘save lives’, and what we can do about it. BMJ 2016;352:h6080.

Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945-56.

Welch HG, Robertson DJ. Colorectal cancer on the decline: why screening can’t explain it all. N Engl J Med 2016;374:1605-7.

Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO, 1968

10.

Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.CrossRef

11.

Harding Center for risk literacy/Max Planck Institute for Human Development. Berlin: Harding-Zentrum für Risikokompetenz/ Max-Planck-Institut für Bildungsforschung; 2016. https://www.harding-center.mpg.de/de, geraadpleegd september 2016.

12.

Legemate DA, Koelemay MJ, Ubbink DT. Number unnecessarily treated in relation to harm: a concept physicians and patients need to understand. Ann Surg 2016;263:855-6.CrossRef

13.

Wegwarth O, Schwartz LM, Woloshin S, Gaissmaier W, Gigerenzer G. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med 2012;156:340-9.CrossRef

14.

Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4.CrossRef

15.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev 2013;(1):CD004720.

16.

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2013;(6):CD001877.

17.

Siebert U, Sroczynski G, Hillemanns P, Engel J, Stabenow R, Stegmaier C, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006;16:185-92.CrossRef

18.

van der Graaf Y, Zielhuis GA, Vooijs GP. Cervical cancer mortality in the Netherlands. Int J Epidemiol 1988;17:270-6.CrossRef

19.

de Glas NA, de Craen AJ, Bastiaannet E, Op ‘t Land EG, Kiderlen M, van de Water W, et al. Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. BMJ 2014;349:g5410.CrossRef

20.

Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011;343:d4411.CrossRef

21.

Autier P. Efficient treatments reduce the cost-efficiency of breast cancer screening. Ann Intern Med 2016;164:297-8.CrossRef

22.

Birnbaum J, Gadi VK, Markowitz E, Etzioni R. The effect of treatment advances on the mortality results of breast cancer screening trials: a microsimulation model. Ann Intern Med 2016;164:236-43.CrossRef

23.

Ait Ouakrim D, Pizot C, Boniol M, Malvezzi M, Boniol M, Negri E, et al. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ 2015;351:h4970.

24.

Krogsbø11 LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General healthchecks in adults for reducing morbidity and mortality from disease. CochraneDatabase Syst Rev 2012;(10):CD009009.

25.

van Brabandt H, Desomer A, Gerkens S, Neyt M. Harms and benefits of screening young people to prevent sudden cardiac death. BMJ 2016;353:i1156.

Titel: 8 Vroegdiagnostiek, total body scans en bevolkingsonderzoek: verbetering of valse verwachting?
Auteur: Yolanda van der Graaf
Uitgeverij: Bohn Stafleu van Loghum
Boek: De dokter en het geld
Print ISBN: 978-90-368-2055-4

Elektronisch ISBN: 978-90-368-2056-1

Copyright: 2018
DOI: https://doi.org/10.1007/978-90-368-2056-1_12

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen